EU/3/11/926

About

On 27 October 2011, orphan designation (EU/3/11/926) was granted by the European Commission to Adienne S.r.l, Italy, for recombinant human minibody against complement component C5 for the treatment of primary membranoproliferative glomerulonephritis.

In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2019 on request of the Sponsor.

Key facts

Active substance
Recombinant human minibody against complement component C5
Disease / condition
Treatment of primary membranoproliferative glomerulonephritis
Date of decision
27/10/2011
Outcome
Withdrawn
Orphan decision number
EU/3/11/926

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

ADIENNE S.r.l.S.U.
Via Galileo Galilei, 19
20867 Caponago (MB)
Italy
Tel. +39 02 4070 0445
Fax +39 02 9574 5179
E-mail: adienne@adienne.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating